Learning Objectives:

1.     Better understand obesity-associated hypertension and impact of new weight loss drugs on blood pressure.

2.    Understand the ongoing development of RNA-based therapeutics in the treatment of hypertension.

3.    Understand the ongoing development of aldosterone synthase inhibitors to treat hypertension, cardiovascular and kidney disease.

Session date: 
10/21/2024 - 5:00pm to 6:00pm CDT
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Luke Laffin, M.D.